As investors, we are often looking to diversify our portfolios. Especially with the wild AI craze in the past year, many investors already hold positions in AI or other technology companies. Adding a variety of stocks from different sectors in your portfolio can help reduce risk. It lessens your dependence on returns in one sector. Diversification with the top healthcare stocks to buy can help spread out your risk in case any one sector collapses.Although healthcare stocks aren’t discussed as much right now ...

Aging stocks (or longevity stocks) are drawing attention from investors for obvious reasons. The Baby Boomer generation is now almost fully retired, and Gen X is right on its heels. It is a profitable trend that’s not going away anytime soon.There are many ways to invest in an aging population. An obvious choice is healthcare stocks. The advancements in medical technology allow individuals to enjoy a better quality of life for much longer.Of course, as many Gen X and Millennial children can attest to, that ...

CHARLOTTESVILLE, Va., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco on Thursday, January 11, 2024, at 10:30 a.m. PT (1:30 p.m. ET). The live webcast may be accessed under the Investors t ...

Q3 2023 Financial Results & Business Update November 13, 2023 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking stateme ...

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2023 Earnings Conference Call November 13, 2023 08:00 AM ET Company Participants Alex Braun - Head-IR Daniel O'Connell - CEO Eric Siemers - Chief Medical Officer Matt Zuga - CFO & Chief Business Officer Conference Call Participants Thomas Shrader - BTIG Pete Stavropoulos - Cantor Fitzgerald Colin Bristow - UBS Presentation Operator Good day, ladies and gentlemen. Thank you for standing by. Welcome to Acumen Pharma Third Quarter 2023 Conference Call and Webcast ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ___________________________ FORM 10-Q ___________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_________to_________ Commission File Number: 001-40551 ___________________________ Acumen Pharmaceuti ...

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q2 2023 Earnings Conference Call August 8, 2023 8:00 AM ET Company Participants Alex Braun - Head-Investor Relations Dan O'Connell - Chief Executive Officer Eric Siemers - Chief Medical Officer Matt Zuga - Chief Financial Officer & Chief Business Officer Conference Call Participants Colin Bristow - UBS Paul Matteis - Stifel Tom Shrader - BTIG Pete Stavropoulos - Cantor Fitzgerald Charlie Yang - Bank of America Operator Thank you for standing by, and welcome to the ...

Q2 2023 Financial Results & Business Update August 8, 2023 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking stateme ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ___________________________ FORM 10-Q ___________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_________to_________ Commission File Number: 001-40551 ___________________________ Acumen Pharmaceuticals, ...

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q1 2023 Earnings Conference Call May 9, 2023 8:00 AM ET Company Participants Alex Braun - Head IR Daniel O'Connell - President and CEO Eric Siemers - Chief Medical Officer Matt Zuga - CFO and Chief Business Officer Conference Call Participants Tom Shrader - BTIG Judah Frommer - Credit Suisse Charlie Yang - BofA Operator Good day, and thank you for standing by. Welcome to the Acumen Pharma Q1 2023 Conference Call and Webcast. At this time all participants are in a l ...